Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 04, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001506928 | |
Entity Registrant Name | Avinger Inc | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-36817 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-8873453 | |
Entity Address, Address Line One | 400 Chesapeake Drive | |
Entity Address, City or Town | Redwood City | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94063 | |
City Area Code | 650 | |
Local Phone Number | 241-7900 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | AVGR | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 7,435,644 |
Condensed Balance Sheets (Curre
Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 17,342 | $ 19,497 |
Accounts receivable, net of allowance for doubtful accounts of $43 at September 30, 2022 and $6 at December 31, 2021 | 1,554 | 1,393 |
Inventories | 5,047 | 4,601 |
Prepaid expenses and other current assets | 652 | 300 |
Total current assets | 24,595 | 25,791 |
Right of use asset | 2,449 | 3,179 |
Property and equipment, net | 574 | 95 |
Other assets | 333 | 420 |
Total assets | 27,951 | 29,485 |
Current liabilities: | ||
Accounts payable | 612 | 1,394 |
Accrued compensation | 1,344 | 1,609 |
Series A preferred stock dividends payable | 3,382 | 0 |
Accrued expenses and other current liabilities | 669 | 718 |
Leasehold liability, current portion | 1,065 | 985 |
Total current liabilities | 7,072 | 4,706 |
Borrowings, long-term portion | 13,668 | 12,287 |
Leasehold liability, long-term portion | 1,384 | 2,194 |
Other long-term liabilities | 881 | 575 |
Total liabilities | 23,005 | 19,762 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity: | ||
Convertible preferred stock issuable in series, par value of $0.001; Shares authorized: 5,000,000 at September 30, 2022 and December 31, 2021; Shares issued and outstanding: 56,451 at September 30, 2022 and December 31, 2021; aggregate liquidation preference of $56,366 at September 30, 2022 and December 31, 2021 | 0 | 0 |
Common stock, par value of $0.001; Shares authorized: 100,000,000 at September 30, 2022 and December 31, 2021; Shares issued and outstanding: 7,435,644 and 4,778,263 at September 30, 2022 and December 31, 2021, respectively | 7 | 96 |
Additional paid-in capital | 403,133 | 394,380 |
Accumulated deficit | (398,194) | (384,753) |
Total stockholders’ equity | 4,946 | 9,723 |
Total liabilities and stockholders’ equity | $ 27,951 | $ 29,485 |
Condensed Balance Sheets (Cur_2
Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Accounts receivable, allowance for doubtful accounts | $ 43 | $ 6 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 56,451 | 56,451 |
Preferred stock, shares outstanding (in shares) | 56,451 | 56,451 |
Preferred stock, liquidation preference | $ 56,366 | $ 56,366 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 7,435,644 | 4,778,263 |
Common stock, shares outstanding (in shares) | 7,435,644 | 4,778,263 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | $ 2,252 | $ 2,366 | $ 6,272 | $ 7,727 |
Cost of revenues | 1,462 | 1,566 | 4,301 | 5,015 |
Gross profit | 790 | 800 | 1,971 | 2,712 |
Operating expenses: | ||||
Research and development | 1,086 | 1,397 | 3,244 | 4,502 |
Selling, general and administrative | 3,384 | 3,892 | 10,862 | 11,755 |
Total operating expenses | 4,470 | 5,289 | 14,106 | 16,257 |
Loss from operations | (3,680) | (4,489) | (12,135) | (13,545) |
Interest expense, net | (407) | (419) | (1,286) | (1,214) |
Other (expenses) income, net | (4) | (20) | 2,343 | |
Net loss and comprehensive loss | (4,087) | (4,912) | (13,441) | (12,416) |
Accretion of preferred stock dividends | (1,127) | (1,044) | (3,381) | (3,132) |
Deemed dividend arising from beneficial conversion feature of convertible preferred stock | (5,111) | |||
Net loss applicable to common stockholders | $ (5,214) | $ (5,956) | $ (21,933) | $ (15,548) |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.77) | $ (1.25) | $ (3.78) | $ (3.31) |
Weighted average common shares used to compute net loss per share, basic and diluted (in shares) | 6,798 | 4,769 | 5,804 | 4,704 |
Condensed Statements of Stockho
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | January 2022 Public Offering [Member] Preferred Stock [Member] | January 2022 Public Offering [Member] Common Stock [Member] | January 2022 Public Offering [Member] Additional Paid-in Capital [Member] | January 2022 Public Offering [Member] Retained Earnings [Member] | January 2022 Public Offering [Member] | February 2021 Public Offering [Member] Preferred Stock [Member] | February 2021 Public Offering [Member] Common Stock [Member] | February 2021 Public Offering [Member] Additional Paid-in Capital [Member] | February 2021 Public Offering [Member] Retained Earnings [Member] | February 2021 Public Offering [Member] | Series D Preferred Stock [Member] Preferred Stock [Member] | Series D Preferred Stock [Member] Common Stock [Member] | Series D Preferred Stock [Member] Additional Paid-in Capital [Member] | Series D Preferred Stock [Member] Retained Earnings [Member] | Series D Preferred Stock [Member] | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 52,369 | 4,246,306 | ||||||||||||||||||
Balance at Dec. 31, 2020 | $ 0 | $ 85 | $ 380,332 | $ (367,341) | $ 13,076 | |||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units (in shares) | 0 | 13,242 | ||||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units | $ 0 | $ 1 | 0 | 0 | 1 | |||||||||||||||
Employee stock-based compensation | 0 | 0 | 960 | 0 | 960 | |||||||||||||||
Accretion of Series A preferred stock dividends | 0 | 0 | (3,132) | 0 | (3,132) | |||||||||||||||
Net and comprehensive loss | $ 0 | $ 0 | 0 | (12,416) | (12,416) | |||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) | 0 | 500,000 | ||||||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs | $ 0 | $ 10 | $ 13,067 | $ 0 | $ 13,077 | |||||||||||||||
Conversion of preferred stock into common stock (in shares) | (93) | 18,600 | ||||||||||||||||||
Conversion of preferred stock into common stock | $ 0 | $ 0 | 0 | 0 | 0 | |||||||||||||||
Balance (in shares) at Sep. 30, 2021 | 52,276 | 4,778,148 | ||||||||||||||||||
Balance at Sep. 30, 2021 | $ 0 | $ 96 | 391,227 | (379,757) | 11,566 | |||||||||||||||
Balance (in shares) at Jun. 30, 2021 | 52,276 | 4,767,650 | ||||||||||||||||||
Balance at Jun. 30, 2021 | $ 0 | $ 95 | 392,032 | (374,845) | 17,282 | |||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units (in shares) | 0 | 10,498 | ||||||||||||||||||
Issuance of common stock under officers and directors purchase plan and vesting of restricted stock units | $ 0 | $ 1 | 0 | 0 | 1 | |||||||||||||||
Employee stock-based compensation | 0 | 0 | 239 | 0 | 239 | |||||||||||||||
Accretion of Series A preferred stock dividends | 0 | 0 | (1,044) | 0 | (1,044) | |||||||||||||||
Net and comprehensive loss | $ 0 | $ 0 | 0 | (4,912) | (4,912) | |||||||||||||||
Balance (in shares) at Sep. 30, 2021 | 52,276 | 4,778,148 | ||||||||||||||||||
Balance at Sep. 30, 2021 | $ 0 | $ 96 | 391,227 | (379,757) | 11,566 | |||||||||||||||
Balance (in shares) at Dec. 31, 2021 | 56,451 | 4,778,263 | ||||||||||||||||||
Balance at Dec. 31, 2021 | $ 0 | $ 96 | 394,380 | (384,753) | 9,723 | |||||||||||||||
Employee stock-based compensation | 0 | 0 | 127 | 0 | 127 | |||||||||||||||
Accretion of Series A preferred stock dividends | 0 | 0 | (3,381) | 0 | (3,381) | |||||||||||||||
Net and comprehensive loss | $ 0 | $ 0 | 0 | (13,441) | (13,441) | |||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) | 0 | 1,285,603 | 7,600 | 0 | ||||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs | $ 0 | $ 2 | $ 5,194 | $ 0 | $ 5,196 | $ 0 | $ 0 | $ 6,721 | $ 0 | $ 6,721 | ||||||||||
Exercise of pre-funded warrants for common stock (in shares) | 0 | 387,019 | ||||||||||||||||||
Exercise of pre-funded warrants for common stock | $ 0 | $ 0 | 0 | 0 | 0 | |||||||||||||||
Issuance of common stock upon vesting of restricted stock units (in shares) | 0 | 8,590 | ||||||||||||||||||
Issuance of common stock upon vesting of restricted stock units | $ 0 | $ 0 | 0 | 0 | 0 | |||||||||||||||
Conversion of preferred stock into common stock (in shares) | (7,600) | 950,000 | ||||||||||||||||||
Conversion of preferred stock into common stock | $ 0 | $ 1 | 0 | 0 | 1 | |||||||||||||||
Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares) | 0 | 26,169 | ||||||||||||||||||
Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares | $ 0 | $ (92) | 92 | 0 | 0 | |||||||||||||||
Balance (in shares) at Sep. 30, 2022 | 56,451 | 7,435,644 | ||||||||||||||||||
Balance at Sep. 30, 2022 | $ 0 | $ 7 | 403,133 | (398,194) | 4,946 | |||||||||||||||
Balance (in shares) at Jun. 30, 2022 | 56,451 | 6,081,333 | ||||||||||||||||||
Balance at Jun. 30, 2022 | $ 0 | $ 6 | 399,422 | (394,107) | 5,321 | |||||||||||||||
Employee stock-based compensation | 0 | 0 | 39 | 0 | 39 | |||||||||||||||
Accretion of Series A preferred stock dividends | 0 | 0 | (1,127) | 0 | (1,127) | |||||||||||||||
Net and comprehensive loss | $ 0 | $ 0 | 0 | (4,087) | (4,087) | |||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) | 0 | 959,137 | ||||||||||||||||||
Issuance of common stock in public offerings, net of commissions and issuance costs | $ 0 | $ 1 | $ 4,799 | $ 0 | $ 4,800 | |||||||||||||||
Exercise of pre-funded warrants for common stock (in shares) | 0 | 387,019 | ||||||||||||||||||
Exercise of pre-funded warrants for common stock | $ 0 | $ 0 | 0 | 0 | 0 | |||||||||||||||
Issuance of common stock upon vesting of restricted stock units (in shares) | 0 | 8,155 | ||||||||||||||||||
Issuance of common stock upon vesting of restricted stock units | $ 0 | $ 0 | 0 | 0 | 0 | |||||||||||||||
Balance (in shares) at Sep. 30, 2022 | 56,451 | 7,435,644 | ||||||||||||||||||
Balance at Sep. 30, 2022 | $ 0 | $ 7 | $ 403,133 | $ (398,194) | $ 4,946 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities | ||
Net loss | $ (13,441) | $ (12,416) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 133 | 525 |
Amortization of debt issuance costs and debt discount | 63 | 65 |
Stock-based compensation | 127 | 960 |
Noncash interest expense and other charges | 1,318 | 1,151 |
Change in right of use asset | 72 | 102 |
Provision for excess and obsolete inventories | 156 | 97 |
Other non-cash charges | 37 | 3 |
Gain on extinguishment of debt | 0 | (2,353) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (198) | 82 |
Inventories | (1,182) | (733) |
Prepaid expenses and other current assets | (352) | (318) |
Other assets | 15 | (44) |
Accounts payable | (783) | 484 |
Accrued compensation | (265) | (324) |
Accrued expenses and other current liabilities | (49) | 122 |
Other long-term liabilities | 306 | 431 |
Net cash used in operating activities | (14,043) | (12,166) |
Cash flows from investing activities | ||
Purchase of property and equipment | (31) | (18) |
Net cash used in investing activities | (31) | (18) |
Cash flows from financing activities | ||
Net cash provided by financing activities | 11,919 | 13,077 |
Net change in cash and cash equivalents | (2,155) | 893 |
Cash and cash equivalents, beginning of period | 19,497 | 22,185 |
Cash and cash equivalents, end of period | 17,342 | 23,078 |
Noncash investing and financing activities: | ||
Accretion of Series A preferred stock dividends | 3,381 | 3,132 |
Reclassification of right of use asset to prepaid rent | (72) | (102) |
Transfers between inventory and property and equipment | 580 | (7) |
Common Stock [Member] | ||
Cash flows from financing activities | ||
Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs | 6,721 | 0 |
Preferred Stock [Member] | ||
Cash flows from financing activities | ||
Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs | $ 5,198 | $ 13,077 |
Note 1 - Organization
Note 1 - Organization | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization, Nature of Business Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. “OCT”) Liquidity Matters In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2022, September 30, 2022 fourth 2023. August 2022, nine September 30, 2022, January 2022 February 2021. may The Company can provide no not may twelve no 19 If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may one not Public Offerings Past Offerings On February 2, 2021, January 2022 On January 14, 2022, “January 2022 The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning July 14, 2022. five July 14, 2027. five January 2022 January 12, 2027. August 2022 On August 4, 2022, “August 2022 As a result, in the Registered Direct offering, the Company issued (i) 700,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and in the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock (the “Private Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 In addition, the Company issued to the investor in the August 2022 five one February 8, 2028, two August 8, 2024. five August 2022 August 3, 2027. At The Market Offering Agreement On May 20, 2022, may 3, March 29, 2022 April 7, 2022, May 20, 2022. September 30, 2022, nine September 30, 2022, not August 3, 2022, may no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 2. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial information. The results for the three nine September 30, 2022 not December 31, 2022, December 31, 2021 10 December 31, 2021, March 22, 2022. 2 10 December 31, 2021. On March 11, 2022, 1 March 14, 2022. not Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may may Concentration of Credit Risk, and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2022 December 31, 2021. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At September 30, 2022, one December 31, 2021, three nine September 30, 2022, three nine September 30, 2021, The Company believes COVID- 19 The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may Product Warranty Costs The Company typically offers a one Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Beginning balance $ 137 $ 231 $ 187 $ 193 Warranty provision 6 5 10 46 Usage/Release (34 ) (40 ) (88 ) (43 ) Ending balance $ 109 $ 196 $ 109 $ 196 Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of September 30, 2022 2021, no Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss applicable to common stockholders $ (5,214 ) $ (5,956 ) $ (21,933 ) $ (15,548 ) Weighted average common stock outstanding, basic and diluted 6,798 4,769 5,804 4,704 Net loss per share attributable to common stockholders, basic and diluted $ (0.77 ) $ (1.25 ) $ (3.78 ) $ (3.31 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Common stock warrants equivalents 5,541,377 134,109 2,490,263 136,489 Common stock options 303 303 303 285 Convertible preferred stock 56,451 52,276 58,562 52,293 Unvested restricted stock units 7,230 18,986 8,718 20,401 5,605,361 205,674 2,557,846 209,468 Segment and Geographical Information The Company operates and manages its business as one three September 30, 2022 2021, nine September 30, 2022 2021, As of September 30, 2022 December 31, 2021, 1 September 30, 2022 December 31, 2021, no 2 3. no three nine September 30, 2022. Recent Accounting Pronouncements Recently adopted accounting standards In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options January 1, 2022. not Recent accounting standards not In August 2020, No. 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 s Own Equity not 815 first 2024 not |
Note 3 - Inventories
Note 3 - Inventories | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 3. Inventories consisted of the following (in thousands): September 30, December 31, 2022 2021 Raw materials $ 2,863 $ 2,503 Work-in-process 333 1 Finished products 1,851 2,097 Total inventories $ 5,047 $ 4,601 |
Note 4 - Borrowings
Note 4 - Borrowings | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 4. CRG On September 22, 2015, March 29, 2017. September 22, 2015. June 15, 2016 On February 14, 2018, The Company has entered into several amendments to the Loan Agreement (the “Amendments”) with CRG since September 2015, August 10, 2022. 1 December 31, 2023; 2 may December 31, 2023 no 3 December 31, 2023 no 4 December 31, 2025; ( 5 6 2018, 2019 2020; 7 $8 2022, 8 2023, 2024 2025; 9 no December 31, 2020; ( 10 19 not 11 Under the amended Loan Agreement, no first 2024. not first 2024, 2024 2025. December 31, 2025. The Company may no seven The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to 2.0 times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company’s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may As of September 30, 2022, As of September 30, 2022, Year Ending December 31, 2022 (remaining three months of the year) $ — 2023 — 2024 9,045 2025 10,339 19,384 Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2022 (5,446 ) Less: Amount representing debt issuance costs (270 ) Borrowings, long term portion, as of September 30, 2022 $ 13,668 In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of September 30, 2022 December 31, 2021, three September 30, 2022 2021, nine September 30, 2022 2021, three September 30, 2022 2021, nine September 30, 2022 2021, As of September 30, 2022, Paycheck Protection Program On April 23, 2020, The PPP Loan, which was in the form of a promissory note, dated April 20, 2020 ( April 20, 2022 1% six no The PPP Loan was administered by the U.S. Small Business Administration (“SBA”). The SBA was given the authority under the PPP to forgive loans if all employees were kept on the payroll for a required period and the loan proceeds were used for payroll, rent and utilities. The Company applied for debt forgiveness in December 2020. On April 17, 2021, no April 2021 nine September 30, 2021, |
Note 5 - Leases
Note 5 - Leases | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 5. The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease. The Company records deferred rent calculated as the difference between rent expense and the cash rental payments. The lease will expire on November 30, 2024. November 2024, December 1, 2019. September 30, 2022 The operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does provide an implicit rate. The Company’s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for both the three September 30, 2022 2021 nine September 30, 2022 2021 three September 30, 2022 2021 nine September 30, 2022 2021 three September 30, 2022 2021 nine September 30, 2022 2021 September 30, 2022 December 31, 2022, The following table presents the future operating leasehold payments and lease liability included on the balance sheet related to the Company’s operating lease as of September 30, 2022 ( Year Ending December 31, 2022 (remaining three months of the year) $ 293 2023 1,203 2024 1,138 2,634 Less: Imputed interest (185 ) Leasehold liability as of September 30, 2022 $ 2,449 The following table shows right of use (“ROU”) assets and lease liabilities, and the associated financial statement line items, as of September 30, 2022 December 31, 2021 ( Lease-Related Assets and Liabilities Financial Statement Line Items September 30, 2022 December 31, 2021 Right of use assets: Operating lease Right of use asset $ 2,449 $ 3,179 Total right of use assets $ 2,449 $ 3,179 Lease liabilities: Operating lease Leasehold liability, current portion $ 1,065 $ 985 Leasehold liability, long-term portion 1,384 2,194 Total lease liabilities $ 2,449 $ 3,179 |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 6. Purchase Obligations Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.5 million as of September 30, 2022. Legal Proceedings The Company is not may |
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. Equity Convertible Preferred Stock As of September 30, 2022 December 31, 2021, September 30, 2022 December 31, 2021, Series A Convertible Preferred Stock The holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have a liquidation preference of $1,000 per share, no December 31, 2021, September 30, 2022 December 31, 2021, September 30, 2022 2021, nine September 30, 2022 2021, Series B Convertible Preferred Stock The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no no not December 31, 2021, September 30, 2022 December 31, 2021, Series D Convertible Preferred Stock On January 14, 2022, “January 2022 $1,000 nine September 30, 2022, no September 30, 2022. At the time of issuance, the Company evaluated the classification of the Series D preferred stock and determined equity classification was appropriate due to no first The embedded conversion feature was evaluated and bifurcation from the preferred stock equity host was not March 14, 2022, one nine September 30, 2022. Common Stock As of September 30, 2022, Common Stock Warrants As of December 31, 2021, Total Outstanding and Exercisable Underlying Shares of Common Stock Exercise Price per Share Expiration Date Series 1 Warrants issued in the February 2018 Series B financing 8,979,000 44,895 $ 400.00 February 2025 Series 2 Warrants issued in the February 2018 Series B financing 8,709,500 43,548 $ 400.00 February 2025 Warrants issued in the November 2018 financing 8,768,395 43,842 $ 80.00 November 2023 Total as of December 31, 2021 26,456,895 132,265 As of September 30, 2022, Total Outstanding and Exercisable Underlying Shares of Common Stock Exercise Price per Share Expiration Date Series 1 Warrants issued in the February 2018 Series B financing 8,979,000 44,895 $ 400.00 February 2025 Series 2 Warrants issued in the February 2018 Series B financing 8,709,500 43,548 $ 400.00 February 2025 Warrants issued in the November 2018 financing 8,768,395 43,842 $ 80.00 November 2023 Placement agent warrants issued in the January 2022 financing 1,330,000 66,500 $ 10.00 January 2027 Warrants issued in the January 2022 financing 16,150,000 807,500 $ 9.60 July 2027 Pre-funded warrants issued in the August 2022 financing 1,766,864 1,766,864 $ 0.0001 n/a Series A Private Investment Options issued in August 2022 financing 2,853,883 2,853,883 $ 1.502 February 2028 Series B Private Investment Options issued in August 2022 financing 2,853,883 2,853,883 $ 1.502 August 2024 Placement agent Private Investment Options issued in the August 2022 financing 171,233 171,233 $ 2.19 August 2027 Total as of September 30, 2022 51,582,758 8,652,148 January 2022 Pursuant to a purchase agreement entered into on January 14, 2022, July 14, 2022. five July 14, 2027. The Company issued to the placement agent of the January 2022 five January 2022 January 12, 2027. August 2022 Pursuant to a purchase agreement entered into on August 4, 2022, August 2022 no three September 30, 2022, September 30, 2022, The Company issued Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock, collectively referred to as Preferred Investment Options. The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five one February 8, 2028, two August 8, 2024. The Company issued to the placement agent of the August 2022 five August 2022 August 3, 2027. The exercise price and the number of shares of common stock issuable upon exercise of each Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options immediately prior to the fundamental transaction. The Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options, 9.99%) of the Company’s outstanding common stock immediately after giving effect to the exercise. A holder of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options or Placement Agent Preferred Investment Options may, not 9.99%. In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, 50% not not not As of September 30, 2022 December 31, 2021, Stock Plans In January 2015, 2015 “2015 October 14, 2022, 2015 September 30, 2022, 2015 The Company’s RSUs generally vest annually over three Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2021 10,060 $ 24.39 0.72 Awarded — $ — — Released (8,590 ) $ 25.02 — Forfeited (1,053 ) $ 24.25 — Awards outstanding at September 30, 2022 417 $ 11.64 0.42 As of September 30, 2022, September 30, 2022, nine September 30, 2022 2021, three September 30, 2022 2021, nine September 30, 2022 2021 2018 There was no common stock issued under the Company’s Officer and Director Share Purchase Plan (“ODPP”) during either the nine September 30, 2022 2021. May 16, 2022, no |
Note 8 - Stock-based Compensati
Note 8 - Stock-based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 8. Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized during the three nine September 30, 2022 2021, Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenues $ 4 $ 24 $ 18 $ 93 Research and development expenses 11 78 37 274 Selling, general and administrative expenses 24 137 72 593 $ 39 $ 239 $ 127 $ 960 |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 9. On October 14, 2022, 2022 “2022 2015 2015 2015 2015 April 5, 2022. 2015 October 14, 2022. 2015 2015 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Product Warranty Liability [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Beginning balance $ 137 $ 231 $ 187 $ 193 Warranty provision 6 5 10 46 Usage/Release (34 ) (40 ) (88 ) (43 ) Ending balance $ 109 $ 196 $ 109 $ 196 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net loss applicable to common stockholders $ (5,214 ) $ (5,956 ) $ (21,933 ) $ (15,548 ) Weighted average common stock outstanding, basic and diluted 6,798 4,769 5,804 4,704 Net loss per share attributable to common stockholders, basic and diluted $ (0.77 ) $ (1.25 ) $ (3.78 ) $ (3.31 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Common stock warrants equivalents 5,541,377 134,109 2,490,263 136,489 Common stock options 303 303 303 285 Convertible preferred stock 56,451 52,276 58,562 52,293 Unvested restricted stock units 7,230 18,986 8,718 20,401 5,605,361 205,674 2,557,846 209,468 |
Note 3 - Inventories (Tables)
Note 3 - Inventories (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | September 30, December 31, 2022 2021 Raw materials $ 2,863 $ 2,503 Work-in-process 333 1 Finished products 1,851 2,097 Total inventories $ 5,047 $ 4,601 |
Note 4 - Borrowings (Tables)
Note 4 - Borrowings (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Year Ending December 31, 2022 (remaining three months of the year) $ — 2023 — 2024 9,045 2025 10,339 19,384 Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2022 (5,446 ) Less: Amount representing debt issuance costs (270 ) Borrowings, long term portion, as of September 30, 2022 $ 13,668 |
Note 5 - Leases (Tables)
Note 5 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2022 (remaining three months of the year) $ 293 2023 1,203 2024 1,138 2,634 Less: Imputed interest (185 ) Leasehold liability as of September 30, 2022 $ 2,449 |
Right of Use Asset and Liabilities [Table Text Block] | Lease-Related Assets and Liabilities Financial Statement Line Items September 30, 2022 December 31, 2021 Right of use assets: Operating lease Right of use asset $ 2,449 $ 3,179 Total right of use assets $ 2,449 $ 3,179 Lease liabilities: Operating lease Leasehold liability, current portion $ 1,065 $ 985 Leasehold liability, long-term portion 1,384 2,194 Total lease liabilities $ 2,449 $ 3,179 |
Note 7 - Stockholders' Equity (
Note 7 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Total Outstanding and Exercisable Underlying Shares of Common Stock Exercise Price per Share Expiration Date Series 1 Warrants issued in the February 2018 Series B financing 8,979,000 44,895 $ 400.00 February 2025 Series 2 Warrants issued in the February 2018 Series B financing 8,709,500 43,548 $ 400.00 February 2025 Warrants issued in the November 2018 financing 8,768,395 43,842 $ 80.00 November 2023 Total as of December 31, 2021 26,456,895 132,265 Total Outstanding and Exercisable Underlying Shares of Common Stock Exercise Price per Share Expiration Date Series 1 Warrants issued in the February 2018 Series B financing 8,979,000 44,895 $ 400.00 February 2025 Series 2 Warrants issued in the February 2018 Series B financing 8,709,500 43,548 $ 400.00 February 2025 Warrants issued in the November 2018 financing 8,768,395 43,842 $ 80.00 November 2023 Placement agent warrants issued in the January 2022 financing 1,330,000 66,500 $ 10.00 January 2027 Warrants issued in the January 2022 financing 16,150,000 807,500 $ 9.60 July 2027 Pre-funded warrants issued in the August 2022 financing 1,766,864 1,766,864 $ 0.0001 n/a Series A Private Investment Options issued in August 2022 financing 2,853,883 2,853,883 $ 1.502 February 2028 Series B Private Investment Options issued in August 2022 financing 2,853,883 2,853,883 $ 1.502 August 2024 Placement agent Private Investment Options issued in the August 2022 financing 171,233 171,233 $ 2.19 August 2027 Total as of September 30, 2022 51,582,758 8,652,148 |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2021 10,060 $ 24.39 0.72 Awarded — $ — — Released (8,590 ) $ 25.02 — Forfeited (1,053 ) $ 24.25 — Awards outstanding at September 30, 2022 417 $ 11.64 0.42 |
Note 8 - Stock-based Compensa_2
Note 8 - Stock-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of revenues $ 4 $ 24 $ 18 $ 93 Research and development expenses 11 78 37 274 Selling, general and administrative expenses 24 137 72 593 $ 39 $ 239 $ 127 $ 960 |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
Aug. 04, 2022 | Jan. 14, 2022 | Feb. 02, 2021 | Aug. 31, 2022 | Jan. 31, 2022 | Feb. 28, 2021 | Sep. 30, 2022 | Sep. 30, 2022 | May 20, 2022 | Dec. 31, 2021 | |
Retained Earnings (Accumulated Deficit), Total | $ (398,194,000) | $ (398,194,000) | $ (384,753,000) | |||||||
Cash and Cash Equivalents, at Carrying Value, Total | $ 17,342,000 | $ 17,342,000 | $ 19,497,000 | |||||||
Share Price (in dollars per share) | $ 1.15 | $ 1.15 | ||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 8,652,148 | 8,652,148 | 132,265 | |||||||
Class of Warrant or Right, Outstanding (in shares) | 51,582,758 | 51,582,758 | 26,456,895 | |||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||||||
Common Warrants [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 807,500 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.60 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||
Placement agent warrants issued in the January 2022 financing [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 66,500 | 66,500 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,330,000 | 1,330,000 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10 | $ 10 | ||||||||
Registered Direct Pre-funded Warrants [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 784,019 | |||||||||
Series A Preferred Investment Options [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,853,883 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.502 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | |||||||||
Series B Preferred Investment Options [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,853,883 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.502 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | |||||||||
Placement Agent Preferred Investment Options [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 171,233 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.19 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||
Series D Preferred Stock [Member] | ||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |||||||||
Series D Preferred Stock [Member] | Common Warrants [Member] | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 807,500 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9.60 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||
Series D Preferred Stock [Member] | Placement agent warrants issued in the January 2022 financing [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 66,500 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||
August 2022 Public Offering [Member] | ||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 4,400,000 | |||||||||
The Market Offering Agreement (the “ATM Agreement”) [Member] | ||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 800,000 | |||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 585,603 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.67 | $ 1.67 | ||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 1,000,000 | |||||||||
Proceeds from Commissions Received | $ 29,000 | |||||||||
January 2022 Public Offering [Member] | ||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 6,700,000 | $ 6,700,000 | ||||||||
January 2022 Public Offering [Member] | Series D Preferred Stock [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 7,600 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1,000 | |||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ 8 | |||||||||
February 2021 Public Offering [Member] | ||||||||||
Proceeds from Issuance or Sale of Equity, Net | $ 13,000,000 | $ 13,000,000 | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 500,000 | |||||||||
Share Price (in dollars per share) | $ 28.80 | |||||||||
August 2022 Purchase Agreement [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 700,000 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.752 | |||||||||
Sale of Stock, Number of Shares (in shares) | 1,484,019 | |||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 4.4 | |||||||||
Private Placement [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,369,864 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.752 | |||||||||
Private Placement [Member] | Registered Direct Pre-funded Warrants [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,369,864 | |||||||||
Common Stock in June, 2022 [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 259,137 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.56 | $ 1.56 | ||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 400,000 | |||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |||||||||
Share Offering Agreement, Aggregate Offering | $ 7,000,000 | |||||||||
Commission Percentage | 3% | |||||||||
Payments of Stock Issuance Costs | $ 12,000 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Mar. 11, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Number of Reportable Segments | 1 | ||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||||
Number of Major Customers | 1 | 1 | |||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | |||||||
Concentration Risk, Percentage | 11% | 21% | |||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||||||
Number of Major Customers | 1 | 0 | 0 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES | |||||||
Concentration Risk, Percentage | 95% | 94% | 93% | 94% | |||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | |||||||
Concentration Risk, Percentage | 11% | 13% | |||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Zero Customer [Member] | |||||||
Concentration Risk, Percentage | 10% | ||||||
Reverse Stock Split [Member] | |||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 20 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Beginning balance | $ 137 | $ 231 | $ 187 | $ 193 |
Warranty provision | 6 | 5 | 10 | 46 |
Usage/Release | (34) | (40) | (88) | (43) |
Ending balance | $ 109 | $ 196 | $ 109 | $ 196 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net loss applicable to common stockholders | $ (5,214) | $ (5,956) | $ (21,933) | $ (15,548) |
Weighted average common stock outstanding, basic and diluted (in shares) | 6,798 | 4,769 | 5,804 | 4,704 |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.77) | $ (1.25) | $ (3.78) | $ (3.31) |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities (in shares) | 5,605,361 | 205,674 | 2,557,846 | 209,468 |
Common Stock Warrants [Member] | ||||
Antidilutive Securities (in shares) | 5,541,377 | 134,109 | 2,490,263 | 136,489 |
Common Stock Options [ member] | ||||
Antidilutive Securities (in shares) | 303 | 303 | 303 | 285 |
Preferred Stock [Member] | ||||
Antidilutive Securities (in shares) | 56,451 | 52,276 | 58,562 | 52,293 |
Restricted Stock Units (RSUs) [Member] | ||||
Antidilutive Securities (in shares) | 7,230 | 18,986 | 8,718 | 20,401 |
Note 3 - Inventories - Schedule
Note 3 - Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Raw materials | $ 2,863 | $ 2,503 |
Work-in-process | 333 | 1 |
Finished products | 1,851 | 2,097 |
Total inventories | $ 5,047 | $ 4,601 |
Note 4 - Borrowings (Details Te
Note 4 - Borrowings (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||
Jan. 22, 2021 | Apr. 23, 2020 | Feb. 14, 2018 | Apr. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Aug. 10, 2022 | Dec. 31, 2021 | Apr. 17, 2021 | Jun. 15, 2016 | Sep. 22, 2015 | |
Gain (Loss) on Extinguishment of Debt, Total | $ 0 | $ 2,353,000 | |||||||||||
Interest Expense, Total | $ 407,000 | $ 419,000 | 1,286,000 | 1,214,000 | |||||||||
Paycheck Protection Program CARES Act [Member] | |||||||||||||
Proceeds from Issuance of Long-term Debt, Total | $ 2,300,000 | ||||||||||||
Long-term Debt, Total | $ 0 | ||||||||||||
Debt Instrument Interest Forgiven | $ 23,000 | ||||||||||||
Interest Expense, Total | 7,000 | ||||||||||||
Paycheck Protection Program CARES Act [Member] | Other Nonoperating Income (Expense) [Member] | |||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 2,400,000 | ||||||||||||
CRG [Member] | Loan Agreement [Member] | |||||||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 50,000,000 | ||||||||||||
Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement | $ 3,500,000 | ||||||||||||
Debt Instrument, Covenant Compliance, Target Minimum Revenue, Past Twelve Months | 10,000,000 | ||||||||||||
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year | 14,500,000 | ||||||||||||
Debt Instrument, Covenant Compliance Target Minimum Revenue Fourth Year | $ 17,000,000 | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | ||||||||||||
Debt Instrument, Periodic Payment, Total | $ 1,900,000 | ||||||||||||
Long-Term Debt, Maturity, Year Four | 7,500,000 | ||||||||||||
Long-Term Debt, Maturity, Year Five | $ 7,500,000 | ||||||||||||
Debt Instrument, Redemption Initial Prepayment Premium Percentage | 5% | ||||||||||||
Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage | 1% | ||||||||||||
Debt Instrument, Redemption Prepayment Premium Percentage after Fifth Year | 0% | ||||||||||||
Debt Instrument, Financing Fee Percentage | 1.50% | ||||||||||||
Debt Instrument, Final Facility Fee Percentage | 15% | ||||||||||||
Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum | $ 3,500,000 | ||||||||||||
Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall | 2 | ||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 270,000 | 270,000 | $ 333,000 | 1,300,000 | |||||||||
Amortization of Debt Discount (Premium) | 21,000 | 63,000 | 65,000 | ||||||||||
Interest Expense, Debt, Total | $ 480,000 | $ 419,000 | $ 1,400,000 | $ 1,200,000 | |||||||||
CRG [Member] | Loan Agreement [Member] | Series A Preferred Stock Purchase Agreement with CRG [Member] | |||||||||||||
Debt Conversion, Original Debt, Amount | $ 38,000,000 | ||||||||||||
Debt Conversion, Fees and Prepayment Premium Amount | $ 3,800,000 | ||||||||||||
CRG [Member] | Loan Agreement [Member] | First Tranche, Borrowed on September 22, 2015 [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | ||||||||||||
CRG [Member] | Loan Agreement [Member] | Second Tranche, Borrowed on June 15, 2016 [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 |
Note 4 - Borrowings - Schedule
Note 4 - Borrowings - Schedule of Debt (Details) - Loan Agreement [Member] - CRG [Member] $ in Thousands | Sep. 30, 2022 USD ($) |
2022 (remaining three months of the year) | $ 0 |
2023 | 0 |
2024 | 9,045 |
2025 | 10,339 |
Long-Term Debt, Total | 19,384 |
Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2022 | (5,446) |
Less: Amount representing debt issuance costs | (270) |
Borrowings, long term portion, as of September 30, 2022 | $ 13,668 |
Note 5 - Leases (Details Textua
Note 5 - Leases (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Apr. 01, 2019 | |
Lessee, Operating Lease, Liability, Payments, Due, Total | $ 2,634,000 | $ 2,634,000 | $ 5,800,000 | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 2 years 2 months 12 days | 2 years 2 months 12 days | ||||
Lessee, Operating Lease, Discount Rate | 6.50% | |||||
Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly | $ 105,000 | |||||
Operating Lease, Expense | $ 314,000 | $ 314,000 | 942,000 | $ 942,000 | ||
Variable Lease, Cost | 63,000 | 59,000 | 200,000 | 177,000 | ||
Operating Lease, Right-of-Use Asset, Amortization Expense | 271,000 | $ 256,000 | 802,000 | $ 758,000 | ||
Prepaid Rent | $ 86,000 | $ 86,000 | $ 158,000 |
Note 5 - Leases - Future Operat
Note 5 - Leases - Future Operating Lease Payments (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Apr. 01, 2019 |
2022 (remaining nine months of the year), future operating lease payments | $ 293 | ||
2023, future operating lease payments | 1,203 | ||
2024, future operating lease payments | 1,138 | ||
Total, future operating lease payments | 2,634 | $ 5,800 | |
Less: Imputed interest | (185) | ||
Leasehold liability as of September 30, 2022 | $ 2,449 | $ 3,179 |
Note 5 - ROU Assets and Lease L
Note 5 - ROU Assets and Lease Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Operating lease | $ 2,449 | $ 3,179 |
Total right of use assets | 2,449 | 3,179 |
Operating lease | 1,065 | 985 |
Operating Lease, Liability, Noncurrent | 1,384 | 2,194 |
Total lease liabilities | $ 2,449 | $ 3,179 |
Note 6 - Commitments and Cont_2
Note 6 - Commitments and Contingencies (Details Textual) $ in Millions | Sep. 30, 2022 USD ($) |
Purchase Commitment [Member] | |
Purchase Obligation, Total | $ 1.5 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity (Details Textual) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
Oct. 14, 2022 shares | Jan. 14, 2022 USD ($) $ / shares shares | Feb. 14, 2018 | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) shares | Dec. 31, 2021 $ / shares shares | Aug. 31, 2022 $ / shares shares | Aug. 04, 2022 $ / shares shares | Feb. 16, 2018 $ / shares | |
Preferred Stock, Shares Authorized (in shares) | 5,000,000 | 5,000,000 | 5,000,000 | ||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||
Preferred Stock, Shares Issued (in shares) | 56,451 | 56,451 | 56,451 | ||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 56,451 | 56,451 | 56,451 | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 8,652,148 | 8,652,148 | 132,265 | ||||||||
Preferred Stock Redemption Discount | $ | $ 5,111,000 | ||||||||||
Common Stock, Shares Authorized (in shares) | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 7,435,644 | 7,435,644 | 4,778,263 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 51,582,758 | 51,582,758 | 26,456,895 | ||||||||
Share Price (in dollars per share) | $ / shares | $ 1.15 | $ 1.15 | |||||||||
Share-Based Payment Arrangement, Expense | $ | $ 39,000 | $ 239,000 | $ 127,000 | $ 960,000 | |||||||
Common Stock, Shares, Issued (in shares) | 7,435,644 | 7,435,644 | 4,778,263 | ||||||||
Restricted Stock Units (RSUs) [Member] | |||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 100,000 | $ 100,000 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 4 months 24 days | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value | $ | 100,000 | $ 100,000 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ | 14,000 | 0.3 | |||||||||
Share-Based Payment Arrangement, Expense | $ | $ 39,000 | $ 0.2 | $ 100,000 | $ 1 | |||||||
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years | ||||||||||
The 2015 Employee Stock Purchase Plan [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 9,566 | 9,566 | |||||||||
The 2015 Employee Stock Purchase Plan [Member] | Subsequent Event [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 1,750,000 | ||||||||||
Officer and Director Share Purchase Plan [Member] | |||||||||||
Common Stock, Shares, Issued (in shares) | 0 | 0 | 0 | 0 | |||||||
Measurement Input, Expected Term [Member] | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 5.5 | ||||||||||
Measurement Input, Price Volatility [Member] | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 136.61 | ||||||||||
Measurement Input, Discount Rate [Member] | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.51 | ||||||||||
Measurement Input, Expected Dividend Rate [Member] | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||
Common Warrants [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 807,500 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 9.60 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||
Common Stock Warrants, Issued with Series D Convertible Preferred Stock [Member] | |||||||||||
Proceeds from Issuance of Warrants | $ | $ 3,591 | ||||||||||
Placement agent warrants issued in the January 2022 financing [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 66,500 | 66,500 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 10 | $ 10 | |||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,330,000 | 1,330,000 | |||||||||
Registered Direct Pre-funded Warrants [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 784,019 | ||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 387,019 | ||||||||||
Private Pre-funded Warrants [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,369,864 | ||||||||||
Pre-funded Warrants Issued in August 2022 Financing [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,766,864 | 1,766,864 | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,766,864 | 1,766,864 | |||||||||
Series A Preferred Investment Options [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,853,883 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.502 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | ||||||||||
Series B Financing Warrants [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,853,883 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.502 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | ||||||||||
Placement Agent Preferred Investment Options [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 171,233 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 2.19 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||
January 2022 Public Offering [Member] | |||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 4,009 | ||||||||||
Conversion of Series B Preferred Stock into Common Stock [Member] | |||||||||||
Conversion of Stock, Shares Converted (in shares) | 93 | ||||||||||
Conversion of Stock, Shares Issued (in shares) | 18,600 | ||||||||||
Series A Preferred Stock [Member] | |||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 56,366 | 56,366 | 56,451 | ||||||||
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares | $ 1,000 | $ 1,000 | |||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 400 | $ 400 | |||||||||
Dividends, Preferred Stock, Total | $ | $ 1,100,000 | $ 1,000,000 | $ 3,400,000 | $ 3,100,000 | |||||||
Series A Preferred Stock [Member] | CRG [Member] | |||||||||||
Preferred Stock Dividends, Shares (in shares) | 4,175 | ||||||||||
Series A Preferred Stock [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | |||||||||||
Preferred Stock, Dividend Rate, Percentage | 8% | ||||||||||
Series B Preferred Stock [Member] | |||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 85 | 85 | 85 | ||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 5 | $ 5 | $ 5 | ||||||||
Series D Preferred Stock [Member] | |||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | ||||||||||
Conversion of Stock, Shares Converted (in shares) | 7,600 | ||||||||||
Conversion of Stock, Shares Issued (in shares) | 950,000 | ||||||||||
Series D Preferred Stock [Member] | Common Warrants [Member] | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 9.60 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 807,500 | ||||||||||
Series D Preferred Stock [Member] | Placement agent warrants issued in the January 2022 financing [Member] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 66,500 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 10 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||
Series D Preferred Stock [Member] | January 2022 offering [Member] | |||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | ||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 8 | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 7,600 | ||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1,000 | ||||||||||
Preferred Stock, Convertible, Shares Issuable (in shares) | 950,000 | ||||||||||
Series D Preferred Stock [Member] | January 2022 offering [Member] | Common Warrants [Member] | |||||||||||
Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage | 4.99% | ||||||||||
Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election | 9.99% | ||||||||||
Series D Preferred Stock [Member] | January 2022 Public Offering [Member] | |||||||||||
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 8 | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 7,600 | ||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1,000 |
Note 7 - Stockholder's Equity -
Note 7 - Stockholder's Equity - Outstanding Warrants (Details) - $ / shares | Sep. 30, 2022 | Aug. 04, 2022 | Dec. 31, 2021 |
Total outstanding and exercisable (in shares) | 51,582,758 | 26,456,895 | |
Underlying shares of common stock (in shares) | 8,652,148 | 132,265 | |
Series 1 February 2018 Warrants [Member] | |||
Total outstanding and exercisable (in shares) | 8,979,000 | 8,979,000 | |
Underlying shares of common stock (in shares) | 44,895 | 44,895 | |
Exercise price per share (in dollars per share) | $ 400 | $ 400 | |
Series 2 February 2018 Warrants [Member] | |||
Total outstanding and exercisable (in shares) | 8,709,500 | 8,709,500 | |
Underlying shares of common stock (in shares) | 43,548 | 43,548 | |
Exercise price per share (in dollars per share) | $ 400 | $ 400 | |
November 2018 Warrants [Member] | |||
Total outstanding and exercisable (in shares) | 8,768,395 | 8,768,395 | |
Underlying shares of common stock (in shares) | 43,842 | 43,842 | |
Exercise price per share (in dollars per share) | $ 80 | $ 80 | |
Placement agent warrants issued in the January 2022 financing [Member] | |||
Total outstanding and exercisable (in shares) | 1,330,000 | ||
Underlying shares of common stock (in shares) | 66,500 | ||
Exercise price per share (in dollars per share) | $ 10 | ||
Warrants Issued in the January 2022 Financing [Member] | |||
Total outstanding and exercisable (in shares) | 16,150,000 | ||
Underlying shares of common stock (in shares) | 807,500 | ||
Exercise price per share (in dollars per share) | $ 9.60 | ||
Pre-funded Warrants Issued in August 2022 Financing [Member] | |||
Total outstanding and exercisable (in shares) | 1,766,864 | ||
Underlying shares of common stock (in shares) | 1,766,864 | ||
Exercise price per share (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Series A Private Investment Options Issued in August 2022 Financing [Member] | |||
Total outstanding and exercisable (in shares) | 2,853,883 | ||
Underlying shares of common stock (in shares) | 2,853,883 | ||
Exercise price per share (in dollars per share) | $ 1.502 | ||
Series B Private Investment Options Issued in August 2022 Financing [Member] | |||
Total outstanding and exercisable (in shares) | 2,853,883 | ||
Underlying shares of common stock (in shares) | 2,853,883 | ||
Exercise price per share (in dollars per share) | $ 1.502 | ||
Placement Agent Private Investment Options Issued in August 2022 Financing [Member] | |||
Total outstanding and exercisable (in shares) | 171,233 | ||
Underlying shares of common stock (in shares) | 171,233 | ||
Exercise price per share (in dollars per share) | $ 2.19 |
Note 7 - Stockholders' Equity -
Note 7 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Awards outstanding, shares (in shares) | 10,060 | |
Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) | $ 24.39 | |
Awards outstanding, Weighted Average Remaining Contractual Term (Year) | 5 months 1 day | 8 months 19 days |
Awarded, shares (in shares) | 0 | |
Awarded, Weighted Average Grant Date Fair Value (in dollars per share) | $ 0 | |
Released, shares (in shares) | (8,590) | |
Released, Weighted Average Grant Date Fair Value (in dollars per share) | $ 25.02 | |
Forfeited, shares (in shares) | (1,053) | |
Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share) | $ 24.25 | |
Awards outstanding, shares (in shares) | 417 | 10,060 |
Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) | $ 11.64 | $ 24.39 |
Note 8 - Stock-based Compensa_3
Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Allocated Share-based Compensation Expense | $ 39 | $ 239 | $ 127 | $ 960 |
Cost of Sales [Member] | ||||
Allocated Share-based Compensation Expense | 4 | 24 | 18 | 93 |
Research and Development Expense [Member] | ||||
Allocated Share-based Compensation Expense | 11 | 78 | 37 | 274 |
Selling, General and Administrative Expenses [Member] | ||||
Allocated Share-based Compensation Expense | $ 24 | $ 137 | $ 72 | $ 593 |
Note 9 - Subsequent Events (Det
Note 9 - Subsequent Events (Details Textual) - The 2015 Employee Stock Purchase Plan [Member] - Subsequent Event [Member] | Oct. 14, 2022 shares |
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 1,750,000 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 1,805,839 |